BCBrayan Daniel Cordoba-Melo

Brayan Daniel Cordoba-Melo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brayan Daniel Cordoba-Melo has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Outcomes of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Cohort Study From a Latin American Care Center

    by Miller Giraldo‐Sandoval, Fernando Andrés Guerrero‐Pinedo, Ángela María Herrera‐Peña, Juan David Agrado‐Torres, Julián Mauricio Cortés‐Colorado, Frank Cañón‐Estrada, Carlos Andrés Mejía‐Gómez, María Alejandra Londoño‐Osorio, Juan Andrés Muñoz‐Ordoñez, Valeria Azcarate‐Rodríguez, et al.

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension arising from persistent major pulmonary artery obstruction after pulmonary embolism. Pulmonary endarterectomy (PEA) remains the standard of care, but up to 40% of patients in European and US registries are inoperable; balloon pulmonary angioplasty (BPA) has emerged as a more accessible interventional modality for suitable patients. This retrospective single‐center cohort study evaluated functional improvement, hemodynamic response, and mortality in patients with CTEPH ineligible for PEA who underwent BPA at a Colombian institution (May 2022–October 2025). Risk was stratified using COMPERA 2.0. The primary outcome was improvement of at least one New York Heart Association (NYHA) functional class; secondary outcomes were change in mean pulmonary arterial pressure (mPAP) and all‐cause mortality during follow‐up. Of 33 patients (median age 63 years; 70% female), 5 (15.1%) were high risk at baseline, 16 (48.4%) intermediate‐high, 10 (30.3%) intermediate‐low, and 2 (6%) low risk. After BPA, 19 patients (58%) improved NYHA class (95% CI, 39.2%–74.5%), and mPAP fell from 60 (IQR 50–68) to 40 mmHg (IQR 37–48) after a median of three sessions (IQR 2–4) (mean paired reduction 14.05 mmHg, 95% credible interval 9.81–18.07; Hedges’ g = 1.22, 95% CI 0.77–1.66). Two deaths (6.0%) occurred, both in high‐risk patients. BPA improved NYHA class and pulmonary hemodynamics in severe, inoperable CTEPH, with a low complication rate despite advanced baseline disease. COMPERA 2.0 stratified baseline severity but did not predict the magnitude of hemodynamic response to BPA, consistent with the mechanical nature of the disease.

  • Open Access

    LDL-C achievement in patients with coronary artery disease: a study protocol for the EDHIPO-MARCA retrospective registry

    by Brayan Daniel Cordoba-Melo, Juan Pablo Arango-Ibanez, Santiago Posso-Marín, Álvaro J Ruiz, Dora Inés Molina, Juan Esteban Gomez-Mesa

    Introduction: Elevated lipid profiles increase the risk of atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality worldwide. Despite the availability of lipid-lowering therapy (LLT), adherence to therapy and achievement of Low-Density Lipoprotein Cholesterol (LDL-C) target levels remain suboptimal. Coronary artery disease (CAD) presents substantial public health challenges, with LDL-C goal attainment rates reported to be between 30.0% and 54.0%. The EDHIPO MARCA (Evaluación De adherencia a la terapia HIPOlipemiante en pacientes de Muy Alto Riesgo CArdiovascular) study aims to evaluate LDL-C target achievement among Colombian patients with CAD. Methods and analysis: This is a retrospective and multicentre study aiming to evaluate LDL-C target achievement within 12 months of coronary angiography across multiple Colombian institutions. Data will be retrospectively extracted from medical records corresponding to the years 2011, 2012, 2016, 2017, 2021 and 2022, which were selected to correspond with the European Society of Cardiology/European Atherosclerosis Society guideline updates. Inclusion criteria included patients ≥18 years old with confirmed CAD and LDL-C reports recorded during outpatient follow-up. The study will evaluate a minimum sample size of 5000 patients, with data collected through medical records and managed using the REDCap platform. Statistical analyses will be conducted to assess LDL-C target achievement, associated factors and temporal trends using mixed-effects models. Uncertainty will also be explored through sensitivity analysis. The EDHIPO MARCA study will provide key insights into LDL-C target achievement in Colombia, contributing to both regional and global CAD management. Its findings will be used to help shape public health policies and serve as a foundation for future prospective research and interventions aimed at mitigating the burden of cardiovascular disease. Ethics and dissemination: This study was approved by the Comité de Ética en Investigación Biomédica of Fundación Valle del Lili, the coordinating institution and creator of the study protocol. Each participating centre will obtain approval from its local ethics committee prior to data collection. Data will be collected in a de-identified manner, ensuring confidentiality. In accordance with Colombian Resolution 8430, this study is classified as 'no-risk', and informed consent was not required. The findings will be disseminated through scientific events and published in international peer-reviewed journals to contribute to cardiovascular disease management and public health policies.


  • Open Access

    From guidelines to practice: LDL-C achievement in very high cardiovascular risk patients – analysis of the EDHIPO MARCA registry

    by Brayan Daniel Cordoba-Melo, Sebastián Seni-Molina, Juan Pablo Arango-Ibanez, Milton René Ayala, José Fidel Tatis-Méndez, Viviana Quintero Yepez, Luz Aída Mejía Cadavid, José D. Cruz-Cuevas, Nicolás Ariza-Ordóñez, Andrés Buitrago, et al.

    Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, with dyslipidemia playing a key role in its progression. Despite advances in lipid-lowering therapy (LLT), LDL-C (Low-Density Lipoprotein Cholesterol) goal achievement remains suboptimal. This study evaluated LDL-C goal attainment in Colombian patients with very high cardiovascular risk (CVR) due to coronary artery disease (CAD) following ESC/EAS guidelines updates. EDHIPO MARCA (Evaluación De adherencia a la terapia HIPOlipemiante en pacientes de Muy Alto Riesgo CArdiovascular) is a retrospective, multicenter study assessing LDL-C goal achievement in patients with CAD. Data were collected from previous coronary angiogram reports and medical records across 11 Colombian healthcare institutions with certified interventional cardiology services. Patients with CAD who had at least one follow-up LDL-C measurement and an LLT prescription within 12 months post-angiogram were included. LDL-C goal attainment was assessed across three periods—2011–2012, 2016–2017, and 2021–2022—corresponding to the updates of ESC/EAS guidelines (2011, 2016, and 2019, respectively). The LDL-C goals were <70 mg/dL for the first two periods and <55 mg/dL for the most recent one. LDL-C was measured or estimated using the Friedewald equation. Descriptive analyses were performed. A total of 1,788 patients were included, with a median age of 66 years (IQR: 59–74), and 70.7% were male. Hypertension (67.5%) and overweight (40.8%) were the most common comorbidities. At discharge, statins were prescribed in 84.1% (95% CI: 82.4–85.8%) of patients, increasing to 99.1% (95% CI: 98.6–99.5%) at the end of follow-up (median 6.8 months); PCSK9 inhibitors were prescribed in 1.5%, exclusively in 2019. At the end of follow-up, 36.6% (95% CI: 34.3%, 38.8%) achieved LDL-C goals. By guideline period, goal attainment was 12.1% (95% CI: 5.4%, 18.8%) in 2011, 42.3% (95% CI: 37.9%, 46.8%) in 2016, and 36.2% (95% CI: 33.5%, 38.9%) in 2019. By number of follow-ups, LDL-C goal achievement increased from 32.9% (1 follow-up) to 44.0% (4 follow-ups). Despite widespread LLT use, LDL-C target achievement remains suboptimal. Frequent follow-up and greater use of combination therapy beyond statins may be essential to improve lipid control in very high CVR patients.


  • Open Access

    Factorial Structure of the Patient Health Questionnaire-9 in long-term survivors of severe COVID-19 (Preprint)

    by Juan Carlos Rivas, Anita Restrepo, Mario Miguel Barbosa, Brayan Daniel Córdoba-Melo, María Corina Ochoa-Rojas, Carlos Alberto Miranda-Bastidas, Andrés Felipe Casanova Rojas, Andrés Fernando Mina Sánchez, Andrea Alejandra Arteaga-Tobar, José Rafael Tovar Cuevas, et al.

    BACKGROUND Previous investigations related to the factor structure of the Patient Health Questionnaire (PHQ-9) have yielded inconclusive results, and there is little consensus about the optimal arrangement of its components. OBJECTIVE This study aim to examine the psychometric properties of the nine-item Patient Health Questionnaire (PHQ-9) in a sample of long-term survivors of severe COVID-19. METHODS The PHQ-9 was administered to 177 patients who were categorized as having suffered previous severe COVID-19 and were followed up to 20 months after this event. Exploratory and confirmatory factor and reliability analyses were performed. RESULTS The one-factor model of PHQ-9 was determined to best fit the sample and demonstrated good psychometric properties and high internal consistency. The factor loadings for the two-factor structure were not consistent with theoretical frameworks of depression and demonstrated lower internal consistency. Subsequent confirmatory analysis indicated a good model fit for the one-factor model CONCLUSIONS The single-factor PHQ-9 was shown to be a valid and reliable instrument for assessing depression in the current sample of patients with history severe COVID-19, followed up to 20 months after this event

  • Open Access

    American Registry of Ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients

    by Juan Esteban Gómez‐Mesa, Juliana María Gutiérrez‐Posso, Manuela Escalante‐Forero, Brayan Daniel Córdoba‐Melo, Paula Andrea Cárdenas‐Marín, Eduardo R. Perna, Mádelyn Raquel Valle‐Ramos, Germán Camilo Giraldo‐González, Noel Alberto Flórez‐Alarcón, Ida Fabiola Rodríguez‐Caballero, et al.

    Background: About 80% of cardiovascular diseases (including heart failure [HF]) occur in low‐income and developing countries. However, most clinical trials are conducted in developed countries.Hypothesis: The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America.Methodology: Descriptive, observational, prospective, and multicenter registry, which includes patients >18 years with HF in an outpatient or hospital setting. Collected information is stored in the REDCap electronic platform. Quantitative variables are defined according to the normality of the variable using the Shapiro–Wilk test.Results: This analysis includes data from the first 1000 patients recruited. 63.5% were men, the median age of 66 years (interquartile range 56.7–75.4), and 77.6% of the patients were older than 55 years old. The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta‐blockers (BB), 77.4% for angiotensin‐converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor‐neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium–glucose cotransporter type‐2 inhibitors (SGLT2i). The main cause of decompensation in hospitalized patients was HF progression (64.4%), and the predominant hemodynamic profile was wet‐warm (68.3%).Conclusions: AMERICCAASS is the first continental registry to include hospitalized or outpatient patients with HF. Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two‐thirds do not receive SGLT2i.